A. Hanker

Molecular Biology · 2020

A researcher in the Science corpus: 1 paper; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom A. Hanker trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Carlos L. Arteaga
  2. K. Flaherty
  3. J. Engelman
  4. J. Baselga
  5. Jason S. Carroll
  6. G. Hortobagyi
  7. Chad Creighton
  8. Mario Campone

Papers from A. Hanker's perspective

Ordered by how strongly the researchers A. Hanker trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer (New England Journal of Medicine)
  2. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. (Journal of Clinical Oncology)
  3. Improved survival with MEK inhibition in BRAF-mutated melanoma. (New England Journal of Medicine)
  4. Genome-wide analysis of estrogen receptor binding sites (Nature Genetics)
  5. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy (Cancer Discovery)
  6. Alpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer (New England Journal of Medicine)
  7. Activating ESR1 mutations in hormone-resistant metastatic breast cancer (Nature Genetics)
  8. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features (Proceedings of the National Academy of Sciences of the United States of America)
  9. BET bromodomain inhibition as a therapeutic strategy to target c-Myc (Cell)
  10. ESR1 mutations as a mechanism for acquired endocrine resistance in breast cancer (Nature Reviews Clinical Oncology)

Their papers